Keros TherapeuticsKROS
KROS
About: Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Employees: 160
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
747% more call options, than puts
Call options by funds: $4.47M | Put options by funds: $528K
75% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 16
38% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 47
38% more capital invested
Capital invested by funds: $1.47B [Q2] → $2.03B (+$558M) [Q3]
8% more funds holding
Funds holding: 151 [Q2] → 163 (+12) [Q3]
3.87% more ownership
Funds ownership: 89.2% [Q2] → 93.07% (+3.87%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 5 (+0) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$43
157%
upside
Avg. target
$62
269%
upside
High target
$111
564%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Truist Securities Srikripa Devarakonda 32% 1-year accuracy 10 / 31 met price target | 157%upside $43 | Buy Maintained | 23 Dec 2024 |
Oppenheimer Andreas Argyrides 59% 1-year accuracy 32 / 54 met price target | 277%upside $63 | Outperform Maintained | 16 Dec 2024 |
Scotiabank Greg Harrison 33% 1-year accuracy 9 / 27 met price target | 163%upside $44 | Sector Outperform Maintained | 13 Dec 2024 |
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 102 / 328 met price target | 181%upside $47 | Buy Reiterated | 13 Dec 2024 |
Wells Fargo Tiago Fauth 70% 1-year accuracy 14 / 20 met price target | 564%upside $111 | Overweight Maintained | 11 Dec 2024 |
Financial journalist opinion
Based on 35 articles about KROS published over the past 30 days
Neutral
Accesswire
1 day ago
Lost Money on Keros Therapeutics, Inc. (KROS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Neutral
Accesswire
1 day ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
1 day ago
Lost Money on Keros Therapeutics, Inc.(KROS)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Neutral
Accesswire
1 day ago
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
Neutral
Accesswire
2 days ago
ATTENTION Keros Therapeutics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect
NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
Neutral
Accesswire
3 days ago
Did Keros Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - KROS
NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Neutral
Accesswire
3 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
Neutral
Accesswire
5 days ago
Levi & Korsinsky Reminds Keros Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - KROS
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Neutral
Accesswire
5 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
Charts implemented using Lightweight Charts™